FreeTheAI

Zealand Pharma Reports Positive Early Trial Safety Data for ZP9830

BullishMedium impact
ZEALDKK 226.30 −1.35%

Zealand Pharma A/S (ZEAL) reported positive early-stage clinical trial results for ZP9830, a Kv1.3 blocker candidate aimed at treating autoimmune conditions. In a four-week Phase 1 multiple ascending dose study, the drug candidate was well tolerated and demonstrated a clean safety profile with no dose-limiting issues. All treatment-emergent adverse events observed during the trial were mild and non-serious.

The successful safety readout helps de-risk ZP9830 as Zealand Pharma expands its drug pipeline outside its core metabolic portfolio. In addition to favorable safety, the drug candidate displayed supportive pharmacokinetics, confirming its suitability for longer-duration studies required in chronic treatment. In recent market trading, shares of Zealand Pharma were down 1.35% to 226.3 DKK.

Looking ahead, Zealand Pharma is currently testing ZP9830 in an ongoing Phase 1b clinical trial focused on psoriasis to evaluate its efficacy. The company also plans to explore evaluating the drug candidate in an additional disease indication in 2027.

Key points

  • Zealand Pharma reported positive four-week Phase 1 safety data for its Kv1.3 blocker ZP9830.
  • No dose-limiting safety findings were reported, and all adverse events were mild and non-serious.
  • Pharmacokinetic findings support longer clinical studies needed for chronic autoimmune conditions.
  • A Phase 1b trial evaluating ZP9830 in patients with psoriasis is currently underway.
  • Zealand Pharma plans to expand research on ZP9830 into an additional disease indication in 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the Phase 1 trial results for Zealand Pharma's ZP9830?

Zealand Pharma reported that ZP9830 was safe and well tolerated in a 4-week Phase 1 trial, with no dose-limiting findings and only mild, non-serious side effects.

What condition is Zealand Pharma currently studying ZP9830 for?

Zealand Pharma is currently conducting a Phase 1b clinical trial evaluating ZP9830 in patients with psoriasis.

When will Zealand Pharma expand testing of ZP9830 to other diseases?

Zealand Pharma plans to explore evaluating ZP9830 in an additional disease indication starting in 2027.